| SEQ_NO | 2 | Date of announcement | 2026/06/25 | Time of announcement | 16:10:52 |
| Subject | Medeon approved to release Directors and its representatives from Non-Competition Restrictions at the Annual Shareholders' Meeting | ||||
| Date of events | 2026/06/25 | To which item it meets | paragraph 21 | ||
| Statement | 1.Date of the shareholders’ meeting resolution:2026/06/25 2.Name and title of the managerial officer with permission to engage in competitive conduct: CENTER LABORATORIES INC. ; Director Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director 3.Items of competitive conduct in which the officer is permitted to engage: Invest in or manage other companies with the same or similar scope of business as Medeon Biodesign, Inc. 4.Period of permission to engage in the competitive conduct: During the period of serving as director of Medeon Biodesign, Inc. 5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): Shares represented at the time of voting: 50,881,799 rights Number of voting rights of shareholders present at the time of voting Votes in favor 48,766,063 votes?APercentage of the total represented share present 95.84% Votes against 447,577 votes?APercentage of the total represented share present 0.87% Votes invalid 0 votes?APercentage of the total represented share present 0.00% Votes abstained 1,668,159 votes?APercentage of the total represented share present 3.27% 6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter ‘N/A’ below): N/A 7.Company name of the mainland China enterprise and the officer’s position in the enterprise: N/A 8.Address of the mainland China enterprise: N/A 9.Operations of the mainland China enterprise: N/A 10.Impact on the company’s finance and business: N/A 11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio: N/A 12.Any other matters that need to be specified: None |
||||